| Author/Editor | Berlec, Aleš; Štrukelj, Borut | |
| Title | Gensko spremenjene mlečnokislinske bakterije kot dostavni sistemi za biološka zdravila | |
| Translated title | Genetically modified lactic acid bacteria as delivery systems for biopharmaceuticals | |
| Type | članek | |
| Vol. and No. | Letnik 59, št. 3 | |
| Publication year | 2008 | |
| Volume | str. 115-120 | |
| ISSN | 0014-8229 - Farmacevtski vestnik | |
| Language | slv | |
| Abstract | Mlečnokislinske bakterije so že stoletja sestavni del človeške prehrane, zato je njihova varnost splošno priznana. Poleg tega so se v novejšem času visoko razvile tehnike, ki omogočajo rekombinantno izražanje proteinov tudi v mlečnokislinskih bakterijah. Zaradi teh razlogov imajo velik potencial kot poceni in učinkoviti dostavni sistemi za dostavo rekombinantnih proteinov na telesne sluznice, predvsem v prebavnem traktu. V razvoju in študijah na živalih so sistemi za dostavo antigenov (cepiv), dostavo proteinov s fiziološko funkcijo in dostavo DNA z namenom cepljenja. Dostava interlevkina IL-10 pri kronični vnetni črevesni bolezni se je izkazala za najbolj obetavno in je bila uspešno testirana v 1. fazi klinične študije na ljudeh. Pred splošno uporabo bo potrebno odgovoriti na vprašanja o varnosti vnosa genskega materiala, ker gre za gensko spremenjene organizme, ki ne uživajo podpore javnosti.Lactic acid bacteria have been a part of human diet for centuries and their safety is therefore generally recognised. Apart from that, the techniques thatenable recombinant protein expression in lactic acid bacteria have recently developed. This is why lactic acid bacteria could serve as a cheap and efficient delivery system for recombinant protein delivery to body mucosa,especially in gastrointestinal tract. Systems for antigen (vaccine) delivery, delivery of proteins with physiological function and for DNA delivery are under development and in animal testing. The delivery of interleukin IL-10 in inflammatory bowel disease is the most promising and was successfully tested in phase I human clinical trial. Before the widespread use, questions regarding safety of genetic material introduction will have to be answered, since these are genetically modified organisms, which are not well accepted by the general public. | |
| Keywords | mlečnokislinske bakterije rekombinantno izražanje dostavni sistem IL-10 gensko spremenjeni organizmi |